Pharma Mar SA
MAD:PHM

Watchlist Manager
Pharma Mar SA Logo
Pharma Mar SA
MAD:PHM
Watchlist
Price: 75.3 EUR -0.4% Market Closed
Market Cap: 1.3B EUR
Have any thoughts about
Pharma Mar SA?
Write Note

Pharma Mar SA
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pharma Mar SA
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Pharma Mar SA
MAD:PHM
Net Income (Common)
€622k
CAGR 3-Years
-78%
CAGR 5-Years
N/A
CAGR 10-Years
-27%
Grifols SA
MAD:GRF
Net Income (Common)
€59.3m
CAGR 3-Years
-54%
CAGR 5-Years
-37%
CAGR 10-Years
N/A
Oryzon Genomics SA
MAD:ORY
Net Income (Common)
-€3.4m
CAGR 3-Years
0%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Biotechnology Assets SA
MAD:BST
Net Income (Common)
-€3.1m
CAGR 3-Years
-58%
CAGR 5-Years
23%
CAGR 10-Years
N/A
No Stocks Found

Pharma Mar SA
Glance View

Market Cap
1.3B EUR
Industry
Biotechnology

Pharma Mar SA is a biopharmaceutical holding company, which engages in research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. The company is headquartered in Colmenar Viejo, Madrid and currently employs 477 full-time employees. The company went IPO on 2015-11-02. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The firm is active globally.

PHM Intrinsic Value
33.2 EUR
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Pharma Mar SA's Net Income (Common)?
Net Income (Common)
622k EUR

Based on the financial report for Sep 30, 2024, Pharma Mar SA's Net Income (Common) amounts to 622k EUR.

What is Pharma Mar SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-27%

Over the last year, the Net Income (Common) growth was -96%. The average annual Net Income (Common) growth rates for Pharma Mar SA have been -78% over the past three years , and -27% over the past ten years .

Back to Top